According to the National Institutes of Health, lower respiratory infections are more prevalent worldwide than HIV, malaria, cancer and heart attacks. Those that suffer from chronic obstructive pulmonary disease, cystic fibrosis or asthma are especially prone reports the journal PLOS Medicine. Treatment can be especially difficult when it’s unclear if the cause is a virus, bacterium or fungus.

The typical Western practice of ingesting pills spreads drugs throughout the body instead of treating only the airside of the lungs, where the problem is located. It’s better to target the active treatment agent only where it’s needed. A study in the European Journal of Clinical Micriobiology & Infectious Diseases suggests delivering a fine-droplet mist from a nebulizer directly atop the invading pathogens and replenishing often to keep the area moist with antimicrobials. This can achieve far greater local dosing with far lower systemic penetration. Choose an antimicrobial that kills all three potential types of pathogens so the physician won’t need to guess the proper drug or try them sequentially.

A more natural option is to avoid drugs. Clinical studies by the Klearsen Corporation and laboratory work at National Jewish Hospital have shown that locally administering an enhanced aqueous colloid of silver in the recommended manner will clear even the most stubborn pathogens. Plus, it has no adverse side effects.

When dosing with a liquid colloid of silver concentration of 50 parts per million (ppm) or more, the suggested protocol is usually three milliliters, three times per day. For acute infections, the three-milliliter dose can be administered every two waking hours. Using a nebulizer is essential to achieve the effective micro-droplets required to reach all areas of the lungs. Inhaling the nebulized mist deep into the lungs will coat the invading pathogens. Note that a vaporizer isn’t suitable because its steam delivery will leave the active ingredients behind.

Steven Frank has researched respiratory infection therapies for 15 years and holds three related patents. Study sites include the Institute for Tuberculosis Research, National Jewish Hospital and Klearsen Corporation. He presented Respiratory Clinical Trial results to the American Naturopathic Medical Association in 2006. He can be reached at [email protected].